Phathom Pharmaceuticals Inc
NASDAQ:PHAT

Watchlist Manager
Phathom Pharmaceuticals Inc Logo
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Watchlist
Price: 9.75 USD 2.42% Market Closed
Market Cap: 581m USD
Have any thoughts about
Phathom Pharmaceuticals Inc?
Write Note

Wall Street
Price Targets

PHAT Price Targets Summary
Phathom Pharmaceuticals Inc

Wall Street analysts forecast PHAT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PHAT is 23.02 USD with a low forecast of 12.12 USD and a high forecast of 29.4 USD.

Lowest
Price Target
12.12 USD
24% Upside
Average
Price Target
23.02 USD
136% Upside
Highest
Price Target
29.4 USD
202% Upside

PHAT Last Price Targets
Phathom Pharmaceuticals Inc

The latest public price target was made on Aug 8, 2024 by Paul Choi from Goldman Sachs , who expects PHAT stock to rise by 23% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Paul Choi
Goldman Sachs
12 USD
Upside 23%
3 months ago
Aug 8, 2024
Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs
StreetInsider
Matthew Caufield
H.C. Wainwright
28 USD
Upside 187%
3 months ago
Jul 19, 2024
H.C. Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)
StreetInsider
Annabel Samimy
Stifel Nicolaus
24 USD
Upside 146%
6 months ago
May 2, 2024
Phathom Pharmaceuticals initiated with a Buy at Stifel
TheFly
Joseph Stringer
Needham
26 USD
Upside 167%
10 months ago
Jan 5, 2024
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
Benzinga
Paul Choi
Goldman Sachs
Price Target 12 USD
Upside/Downside 23%
View Source
Matthew Caufield
H.C. Wainwright
Price Target 28 USD
Upside/Downside 187%
View Source
Annabel Samimy
Stifel Nicolaus
Price Target 24 USD
Upside/Downside 146%
View Source
Joseph Stringer
Needham
Price Target 26 USD
Upside/Downside 167%
View Source
Phathom Pharmaceuticals Inc Competitors:
Price Targets
688356
Jenkem Technology Co Ltd
53% Upside
GLS
Glenmark Life Sciences Ltd
1% Upside
INVA
Innoviva Inc
9% Downside

Revenue
Forecast

Revenue Estimate
Phathom Pharmaceuticals Inc

The compound annual growth rate of Phathom Pharmaceuticals Inc's revenue for the next 3 years is 734%.

N/A
Past Growth
734%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Phathom Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Phathom Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PHAT's stock price target?
Price Target
23.02 USD

According to Wall Street analysts, the average 1-year price target for PHAT is 23.02 USD with a low forecast of 12.12 USD and a high forecast of 29.4 USD.

What is Phathom Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
734%

The compound annual growth rate of Phathom Pharmaceuticals Inc's revenue for the next 3 years is 734%.

Back to Top